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2352-3042/Copyright ª 2014, ChongqiAbstract Fibroblast growth factors (FGF) and their receptors serve many functions in both
the developing and adult organism. Humans contain 18 FGF ligands and four FGF receptors
(FGFR). FGF ligands are polypeptide growth factors that regulate several developmental pro-
cesses including cellular proliferation, differentiation, and migration, morphogenesis, and
patterning. FGF-FGFR signaling is also critical to the developing axial and craniofacial skel-
eton. In particular, the signaling cascade has been implicated in intramembranous ossification
of cranial bones as well as cranial suture homeostasis. In the adult, FGFs and FGFRs are crucial
for tissue repair. FGF signaling generally follows one of three transduction pathways: RAS/MAP
kinase, PI3/AKT, or PLCg. Each pathway likely regulates specific cellular behaviors. Inappro-
priate expression of FGF and improper activation of FGFRs are associated with various patho-
logic conditions, unregulated cell growth, and tumorigenesis. Additionally, aberrant signaling
has been implicated in many skeletal abnormalities including achondroplasia and craniosynos-
tosis. The biology and mechanisms of the FGF family have been the subject of significant
research over the past 30 years. Recently, work has focused on the therapeutic targeting
and potential of FGF ligands and their associated receptors. The majority of FGF-related ther-
apy is aimed at age-related disorders. Increased understanding of FGF signaling and biology
may reveal additional therapeutic roles, both in utero and postnatally. This review discusses
the role of FGF signaling in general physiologic and pathologic embryogenesis and further ex-
plores it within the context of skeletal development.
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200 C.M. Teven et al.IntroductionThe fibroblast growth factor (FGF) family consists of
structurally related polypeptides involved in several phys-
iologic processes. Highly conserved, these growth factors
are found in thousands of animal species, ranging from
nematode and zebra fish to mouse and human.1 FGFs play a
role in cellular proliferation, migration, and differentia-
tion, mitogenesis, angiogenesis, embyrogenesis, and wound
healing.2 It is by the activation of various signal trans-
duction pathways that FGFs mediate multiple develop-
mental processes.3
Mammals contain 18 FGF types (FGF1eFGF10 and
FGF16eFGF23), which have been grouped into six distinct
subfamilies based on phylogeny and sequence homology.4
FGFs share a similar internal core and have a character-
istically high binding affinity for both heparin and fibro-
blast growth factor receptors (FGFRs). FGFRs are tyrosine
kinase receptors that contain a heparin-binding sequence,
three extracellular immunoglobulin-like domains
(D1eD3), a hydrophobic transmembrane domain, and a
split intracellular tyrosine kinase domain.5e7 The
mammalian FGFR family consists of four members
(FGFR1eFGFR4). The amino acid sequences of each re-
ceptor are highly conserved, with differentiation occur-
ring only in their ligand affinity and tissue distribution.8
Characteristic of FGFRs is the acid box, which is a
serine-rich, acidic sequence in the linker between D1 and
D2.4 The acid box and D1 domain are thought to play a
role in receptor autoinhibition.9 The D2eD3 fragment is
required for ligand specificity and binding. In vertebrates,
four genes encode the FGFRs (FGFR1-4), and undergo
alternative splicing in their extracellular domain to pro-
duce many varieties of FGFR1-4 with varying affinities for
their ligands.10
Many data suggest the role of FGF signaling in funda-
mental developmental pathways, including embryogenesis
and the development of organ systems.11 Aberrations in this
pathway have been associated with human disease. Can-
cers from various tissue types have been linked to dysre-
gulated FGF signaling.12 Faulty signaling is also associated
with many congenital syndromes. Many other conditions,
including skeletal dysplasias,13 deafness,14 and lacrimo-
auriculo-dento-digital syndrome,15 result from FGF
signaling errors. Pathological conditions are mostly due to
gain- or loss-of-function mutations in the ligands them-
selves or their receptors.4
The degree of involvement of FGF signaling in both
normal and pathologic development has led to consider-
able research on the therapeutic applications and tar-
geting of the FGF family. Recombinant FGFs and small-
molecule FGF receptor kinase inhibitors have been used in
the treatment of cancer and cardiovascular disease.
Emerging research has also demonstrated their potential
pharmacologic role in preventing chemotherapeutic side
effects as well as treating metabolic syndrome.16 In this
article, we review the current knowledge of FGF signaling
in both physiologic and pathologic development and also
address recent discoveries regarding its therapeutic
potential.The FGF signaling system
Positive regulation of signaling
The FGF signaling cascade is initiated by the binding of FGF
ligands to FGFRs. Following FGF binding, a ligand-
dependent dimerization event takes place in which a
complex is formed that consists of two FGFs, two heparin
sulfate chains, and two FGFRs. Each ligand binds to both
receptors, and the receptors make contact with one
another via a patch on the D2 domain.4 This facilitates the
transphosphorylation of each receptor monomer by an
intrinsic tyrosine kinase domain. At least seven phosphor-
ylation sites have been identified for FGFR1 (Tyr163, Tyr583,
Tyr585, Tyr653, Tyr654, Tyr730, and Tyr766).17e19 Phosphotyr-
osine groups serve as docking sites for adaptor proteins that
regulate downstream signaling.20 The FGF system is asso-
ciated with several downstream signaling pathways; the
best understood are the RAS/mitogen-activating protein
(MAP) kinase pathway, the phosphoinositide 3 (PI3) kinase/
AKT pathway, and the phospholipase C gamma (PLCg)
pathway (Fig. 1).21
The main downstream pathway associated with FGF
signaling is the RAS/MAP kinase pathway. This pathway is
implicated during cellular proliferation and differentia-
tion.22 MAP kinases are serine/threonine-specific protein
kinases that act in response to extracellular stimuli and
regulate various cellular processes. Examples of MAP ki-
nase effectors include c-Jun N-terminal kinase (JNK),
extracellular signal-regulated kinase (ERK), and p38
mitogen-activated kinase.23 After an FGF ligand binds to
its receptor, an integral step in the signaling pathway is
the phosphorylation of the tyrosine residues on the
docking protein fibroblast growth factor receptor sub-
strate 2 alpha (FRS2a). This permits binding of adaptor
proteins that are associated with signal activation.24,25 An
FRS2 complex consisting of FRS2a, guanine nucleotide
exchange factor 2 (GRB2), GRB2-associated binding pro-
tein 1 (GAB1), the son of sevenless (SOS), and tyrosine
phosphatase (SHP2) is then formed that facilitates acti-
vation of the RAS/MAP kinase26 and also PI3 kinase/AKT
pathways.27
The PI3 kinase/AKT pathway is associated with cellular
survival and cell fate determination.26,28 This pathway may
also impact cell polarity.29 Like the RAS/MAP kinase
pathway, the PI3 kinase/AKT pathway is initiated when an
FRS2 signaling complex forms. GAB1 protein then links
activated FGFRs with PI3 kinase. Downstream of PI3 kinase,
phosphoinositide-dependent kinase and AKT (an anti-
apoptotic protein kinase) are activated.21
Another target molecule of activated FGFR is PLCg. This
pathway is activated upon the binding of the PLCgmolecule
to the phosphorylated Tyr766 of the receptor.21 Inositol
triphosphate (IP3) and diacylglycerol (DAG) are then
generated by the hydrolysis of activated PLCg. DAG and
cytoplasmic calcium released from the endoplasmic retic-
ulum in response to IP3 together activate protein kinase C
(PKC).21 Though it has not been completely elucidated, the
PLCg kinase pathway influences cell morphology, migra-
tion, and adhesion.26,28
Figure 1 FGF-FGFR signaling pathway. The signaling cascade
commences upon the formation of an FGF binding complex,
consisting of two FGF ligands, two heparin sulfate chains, and
two FGFRs. Signal transduction largely follows one of three
pathways. The RAS/MAP kinase pathway, initiated upon the
formation of an FRS2 complex, controls cell proliferation and
differentiation. The PI3/AKT pathway is also initiated by the
formation of an FRS2 complex, and regulates cell survival and
fate determination. Finally, upon binding of PLCg to the acti-
vated FGFR, DAG and IP3 are formed, activating PKC. The PLCg
pathway influences cell morphology, migration, and adhesion.
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Like signal activation, mechanisms that attenuate FGF-
FGFR signaling are conserved among many animal species.
These mechanisms, however, are less well understood than
their positive regulation counterparts. In general, down-
stream signal attenuation occurs via the induction of MAPK
phosphatases. First discovered in Drosophilia mela-
nogaster,30 the sprouty (SPRY) family of proteins, which
are MAPK phosphatases, inhibit receptor tyrosine kinase
signaling by directly binding to RAF and blocking subse-
quent MAPK signaling31 or by competing for GRB2 binding,
thereby preventing SOS-mediated RAS activation.12 Inter-
estingly, FGF signaling activates SPRY proteins, which may
be an example of autoinhibition. Additional negative
modulators include the phosphatases MAPK phosphatase 3
(MKP3)32 and SEF.33 MKP3 attenuates the FGF cascade by
dephosphorylating ERK1 and ERK2, molecules important
for MAPK downstream signaling.34 SEF likely mediates its
effects by inhibiting ERK phosphorylation and also byacting at various points along the signaling pathway to
exert its function.34 Further control of signaling takes
place at the level of the receptors. Following activation,
FGFRs may be internalized and subsequently degraded or
recycled.35
FGF signaling in physiologic development
FGF signaling in general embryonic development
The FGF signaling pathway plays many diverse and essential
roles in orchestrating human embryonic development.
Numerous studies, conducted in model organisms over the
past 25 years, have demonstrated that FGF signaling is a
widely utilized regulatory system in early vertebrate
development and has been conserved throughout chordate
evolution.36 FGFs control cell migration during
gastrulation,37e39 epithelio-mesenchymal interactions dur-
ing limb morphogenesis,11,40,41 and neural induction and
patterning42e48 in later stages of development.49
An interesting role of FGFs to organize the migratory
events of gastrulation by functioning as both chemo-
attractants and repellents has been documented.50e53 FGF
signaling is associated with the coordinated cellular
movements of convergent extension and in the epithelial to
mesenchymal transition that marks the onset of gastrula-
tion.54,55 Convergent extension involves the reorganization
of cytoskeletal elements to ensure that cells become
polarized along a similar axis. Polarized cells intercalate
amongst one another, which causes the overall tissue layer
to extend along the perpendicular axis.54 Both FGF and Wnt
signaling have been shown to activate this planar cell po-
larity pathway and propagate the normal activities of
convergent extension during gastrulation.56
In mammalian gastrulation, the process of epithelial-
mesenchymal transition (EMT) takes place after formation
of the primitive streak. During EMT, a fraction of tightly
adherent cells of the epithelial layer lose contact with
neighboring cells and migrate freely from this layer to enter
the primitive streak in order to adopt a mesenchymal
phenotype.36,54 FGFR1 activation facilitates this transition
by mediating down-regulation of E-cadherin-related
cellular adhesions and stimulation of cell migration through
the primitive streak.37,38 This in part was elucidated by the
fact that FGFR1/ mice exhibit recessive embryonic
lethality upon gastrulation57,58 and display retarded
migration of mesoderm precursor cells across the primitive
streak.38,59 Interestingly, FGF8-null mice also display em-
bryonic lethality associated with a failure to develop
through gastrulation.60
FGF signaling also contributes to tissue organization by
directly promoting mesodermal formation while inhibiting
endodermal development.61 During specification of germ
layers, vegetal cells release signals through nodal and
activin pathways to mediate mesoderm identity and
patterning.62,63 FGF2, FGF4, and FGF8 may regulate tran-
scription factors downstream of the nodal and activin
pathways that activate and maintain expression of
mesoderm-specifying genes.64e67
Neural induction is also mediated during gastrulation,
marking a fundamental step of vertebrate central nervous
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cells within the pluripotent dorsal ectoderm is selected to
adopt a neural fate rather than an epidermal fate.49,68
FGF signaling has been shown to facilitate neural induc-
tion in these cells by inhibiting the expression of bone
morphogenetic proteins (BMP) that stimulate epidermal
development.69 Specifically, FGF3 and FGF4 expression
inhibits BMP4 and BMP7 in early neural tissues.52,70,71 FGF
signaling also indirectly inhibits BMP signaling. Expression
of Noggin (NOG) protein, which is a negative inhibitor of
BMP signaling, is increased by FGF stimulation.
Furthermore, FGF signaling results in the inhibitory
phosphorylation of the SMAD1, SMAD5, and SMAD8 tran-
scription factors, which blocks their ability to travel to the
nucleus and activate the transcription of BMP target
genes.36,72e75
FGF ligands also serve as posteriorizing factors during
pattering of the neural plate and directly activate the
transcription of a set of posterior neural genes.76 Studies
manipulating ectopic FGF expression in developing central
nervous systems demonstrate that FGFs convert anterior
neural tissues to more posterior neural cell types.77e84
Within the embryonic isthmic organizer, which is an
important signaling center at the anatomical constriction of
the vertebrate midbrain-hindbrain junction, expression of
FGF8, FGF17, FGF18, and FGFR1 is observed.36,85 There is
strong evidence that FGF signaling modulates early
patterning of the neural tissues via regulation of Hox genes,
a family of homeobox transcription factors that dictate
segmental identity.86 Ectopic application and over-
expression of various FGFs during and after gastrulation
increase the expression of key posterior Hox genes and also
inhibit anterior development.75,87e96 Additionally, deficient
FGFR1 expression is correlated with repression of posterior
Hox genes.87,97
FGF signaling has also been implicated in limb bud
development. In particular, FGF signaling mediates a posi-
tive feedback loop of paracrine signaling between mesen-
chymal and epithelial tissues that pattern the emerging
limb bud and stimulate the outgrowth, morphogenesis, and
maintenance of early limb structure.55 Before the induction
of the apical ectodermal ridge (AER), FGFR1 is expressed in
the underlying mesenchyme; FGFR2 is found in both the
mesenchyme and ectoderm of the presumed future limb
site.98e100 Expression of FGFR1 continues into the later
stages of limb development, where it may play essential
roles in mesodermal patterning of the distal limb fields and
digit formation.101 After induction, the AER expresses
FGF2, FGF4, FGF8, and FGF9, while limb bud mesoderm
expresses FGF2 and FGF10.99 Upon the onset of limb
development, FGF10 secreted by cells of the lateral plate
mesoderm diffuses to the overlying surface ectoderm, and
interacts with FGFR2b to induce formation of the AER su-
perficially.99,102 In response, the AER secretes FGF8, which
acts upon the underlying mesenchymal cells through
FGFR2c to maintain a proliferative state and continue
FGF10 secretion.101,103e106 Secretion of additional FGF10 by
the mesenchymal cells maintains AER expression of
FGF8.107 This positive feedback loop drives further limb
outgrowth by permitting the mesenchyme to maintain the
organizational role of the AER at the propagating edge of
the developing limb, while the AER reciprocally sustains theproximate mesenchyme of the progress zone in a mitoti-
cally active state.108FGF signaling in cranial suture development
FGF signaling plays a critical role in the normal develop-
ment and morphogenesis of the craniofacial skeleton during
embryogenesis and postnatal growth.109 In fact, many
events of normal craniofacial development have been
elucidated during studies examining the etiologic relation-
ship between FGF and FGFR mutations and various skeletal
dysplasias.110,111 FGF signaling is complex and likely in-
teracts with additional signaling pathways during cranio-
facial development.109,110,112e116
In mammals, embryonic tissues of the facial and cranial
bones are derived from neural crest cells.117e122 FGF
signaling induces cranial neural crest formation and is
present in both the epithelia and mesenchyme of the facial
primordia.112,123e127 At six weeks of development, mesen-
chymal condensations begin to foreshadow bones of the
basicranium, followed soon thereafter by those of the
cranial vault bones.128 Delezoide et al observed FGFR1 gene
expression throughout the entire mesenchyme in the head
at this stage as well as strong FGFR2 expression in the
epidermis, pre-bone mesenchymal condensations, and
mesenchymal walls of the cranial vault.128 From the eighth
through thirteenth week of gestation, skull bones develop
via intramembranous ossification. Condensations of
mesenchymal cells located between the dermal mesen-
chyme and the developing meninges simultaneously
differentiate into osteoblasts to give rise to the major
cranial bones. Newly differentiated osteoblasts then syn-
thesize and deposit osteoid matrix radially outwards from
these ossification centers. This osteoid matrix is primarily
composed of type I collagen.129 During early intra-
membranous ossification, there is marked expression of
FGFR1 and FGFR2 and, to a lesser extent, FGFR3 in the cells
of the pre-bone mesenchyme and around the osteoid.128
Indeed, intramembranous ossification of the skull vault is
characterized by co-expression of FGFR1-3 in osteoblast
precursors and osteoblasts.
As mineralization of newly deposited osteoid matrix
progresses outward from ossification centers, the periphery
of the extending bone fields (osteogenic front) develops as
a wedge-shaped proliferation of cells that invade and re-
cruit intervening mesenchymal tissue into these advancing
edges to increase the size of each cranial bone.112,115,129 By
gestation week 18, bone fronts of adjacent cranial bones
are in close proximity, and sutures develop along lines of
approximation.112 The osteogenic fronts of neighboring
cranial bones, undifferentiated mesenchyme between
them, and the adjacent pericranium and dura mater func-
tion as a complex to maintain normal development along
the suture. Morriss-Kay et al demonstrated that in normal
coronal suture development, the maintenance of prolifer-
ating osteogenic cells at the margins of membrane bones
forming the suture requires relatively low FGF levels.110
During normal development, cranial sutures remain in a
patent, unossified state while new intramembranous bone
is formed at the edges of osteogenic fronts. This requires
mesenchymal cells within the suture to remain
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line the bony front differentiate into osteoblasts and pro-
duce additional new bone.130e132 High FGF levels are
associated with osteogenic differentiation. In other words,
in the normal suture there is differential FGF expression
with high levels found in the differentiated region and low
levels found at the suture. At the time of suture fusion,
increased FGF2 levels are observed.133 Cross-talk also exists
between osteoblasts and osteoclasts in maintaining suture
homeostasis on a molecular level as FGF2 directly upregu-
lates RANKL mRNA and indirectly inhibits M-CSF production,
thereby inducing osteoclast differentiation.134 In the
setting of increased receptor activation, whether patho-
logic (see below) or experimental (by the addition of
exogenous FGF), cellular proliferation ceases and suture
fusion ensues.110 Additionally, increased signaling through
FGFR1 is associated with premature fusion while FGFR2 and
FGFR3 signaling maintain osteoprecursor cell proliferation
(Fig. 2).130
FGF signaling between dura mater and overlying cranial
sutures during embryogenesis has implications on proper
development of cranial sutures postnatally.115,129,135 Before
the suture complex can sustain itself through intrinsic sig-
nals, an inductive stimulus of soluble factors emanating
from the dura mater is required during early suture
morphogenesis.129 Along these lines, Kim and colleagues
found that signals from the dura mater regulate proper
suture development prenatally, while signals within the
osteogenic fronts dominate after birth.115 Many of these
signals have been identified as FGF ligands and receptors.Figure 2 Schematic representation of developing coronal suture
ated osteoprogenitor cells expressing FGFR2 and FGFR3 proliferat
fronts. At higher levels of FGF2, osteoprogenitor cells are recruite
FGFR1 expression and deposition of osteoid matrix along the osteoAberrant FGF signaling during development
Given the many integral actions controlled by FGF
signaling, it is no surprise that disruption of the normal
cascade has been implicated in many disease states. Most
mutations that are familial in nature are inherited in
autosomal dominant fashion. New mutations can occur
sporadically, however. Therefore, each mutation is subject
to significant variability with respect to genotypic mutation
and phenotypic expression.8 Regarding FGFRs, many con-
ditions are associated with mutations at specific gene lo-
cations. For example, craniosynostosis is often related to a
mutation within the gene region responsible for the linker
protein between the D2 and D3 extracellular domains of
FGFRs. In addition, mutations around the N-terminal junc-
tion of the transmembrane domain are linked to skeletal
disorders including thanatophoric dysplasia.8 Achondro-
plasia and other disorders of long bone growth are associ-
ated with mutations to the gene responsible for the FGFR
tyrosine kinase domain expressed by chondrocytes at the
physis.136 Several neoplastic conditions have also been
linked to FGFR mutations.136147
Numerous pathologic conditions are associated with
mutated FGF ligands as well. FGF3, which plays a role in
inner ear development, has been linked to inner ear
agenesis and microtia.14 Myogenesis is regulated in part by
FGF6; when mutated, defective muscle regeneration is
present.148 An in depth discussion of the pathophysiology of
mutations of each FGF ligand is beyond the scope of this
review and has been reviewed elsewhere.4 In the following. In the presence of low concentrations of FGF2, undifferenti-
e within the suture mesenchyme between the two osteogenic
d to differentiate into osteoblasts. This leads to increased of
genic fronts.
204 C.M. Teven et al.paragraphs, we detail aberrant FGF signaling in the context
of skeletal disorders.
Achondroplasia
Achondroplasia is the commonest skeletal dysplasia and is
characterized by short stature, rhizomelic limb shortening,
limited elbow extension, frontal bossing, and midface
deficiency. It is passed via autosomal dominant inheritance
but can also occur sporadically. A gain-of-function mutation
of the FGFR3 gene results in decreased inhibition of endo-
chondral ossification.141 In the majority of patients, over
activation of FGFR3 is due to substitution of arginine for
glycine (G380R) within the transmembrane domain.136 The
introduction of a hydrophilic residue into the hydrophobic
receptor domain results in alteration of the signal trans-
duction pathway due to disruption of the alpha helical
structure of the transmembrane protein.140 Additionally,
experimentally-induced under activation of FGFR3 results
in elongation of the vertebral column and long bones.149 It
is thought that mutations causing over activation of FGFR-3
impair chondrocytes within growth plates.136,149 Studies are
now underway regarding whether attenuation of FGFR3
signaling of chondrocytes located within physes in cases of
increased FGFR3 activation can increase bone growth.
Lorget and colleagues demonstrated that an analogue of C-
natriuretic peptide (CNP), which antagonizes downstream
effects of mutated FGFR3, has been used to enhance bone
growth in mice.150,151
Hypochondroplasia
Hypochondroplasia is essentially a milder form of achon-
droplasia that presents with similar radiographic findings in
the limbs and spine.139,141 It follows an autosomal dominant
inheritance pattern. It is distinguished by normal facies and
increased head circumference.141 Greater than half of
hypochondroplasia cases are due to an FGFR3 gene
missense mutation (N540K) in the first tyrosine kinase
domain of the receptor.139,142 This mutation causes a gain-
of-function that results in premature fusion of the growth
plates in the vertebral column and long bones.152 Severe
phenotypes are associated with missense mutations at nu-
cleotides encoding the extracellular region of FGFR3.139,140
The mild phenotype and clinical heterogeneity of hypo-
chondroplasia are likely due to the fact that there are
several potential mutations that may cause it.140 Growth
hormones have been used in an attempt to treat this con-
dition but have been met with mixed results.152 Because
they share a similar pathogenesis, therapeutic options for
achondroplasia may be of benefit for patients with
hypochondroplasia.150,151.
Thanatophoric dysplasia
Thanatophoric dysplasia is a skeletal dysplasia often
incompatible with life. It is characterized by shortened
limbs with normal trunk length, excessive skin folding, a
narrow thorax with shortened ribs, disproportionate mac-
rocephaly, frontal bossing, and protruding eyes.141 Type Ithanatophoric dysplasia is further characterized by micro-
melia with bowed femurs and a cloverleaf skull. Type II
thanatophoric dysplasia is associated with micromelia with
straight femurs, craniosynostosis, and a moderate-to-
severe cloverleaf skull.141,153 Patients with thanatophoric
dysplasia often die of respiratory insufficiency soon after
birth; however, survivors have been reported.141,153 Though
it follows an autosomal dominant inheritance pattern,
virtually all cases are due to sporadic mutations.
Type I thanatophoric dysplasia can result from several
different mutations affecting either extracellular or intra-
cellular domains of FGFR-3. The most common mutation is
the substitution of cysteine for arginine (R248C) in a poly-
peptide within the extracellular domain.143,154,155 Muta-
tions allow for unimpaired cysteine residues to create
disulfide bonds that enable the receptor to dimerize inde-
pendent of the ligand.140 Type II thanatophoric dysplasia is
caused by a point mutation (K650E) to the tyrosine kinase II
domain of FGFR3 that is thought to also result in indepen-
dent dimerization of the receptor.140,143 The FGFR3 muta-
tions associated with the aforementioned skeletal
dysplasias support the notion that FGFR3 signaling is critical
for bone growth regulation (Table 1).
Craniosynostosis
Acrocephalosyndactyly, or craniosynostosis, was first
described by Otto in 1830 as the premature fusion of the
cranial sutures.156 Craniosynostosis can be classified as
simple (one fused suture) or complex (two or more fused
sutures).157 Simple or complex craniosynostosis can be
further classified as primary (sutures prematurely fuse due
to abnormal suture biology) or secondary (normal suture
biology but sutures prematurely fuse due to abnormal
external forces).157 Additional classification as syndromic or
sporadic is based on FGFR gene mutations and associated
phenotype. Syndromic craniosynostosis follows autosomal
dominant inheritance but nearly 75% of craniosynostosis
cases are of the sporadic variety.157 The overall incidence
of craniosynostosis is one in 2500 live births.112,156 In terms
of nonsyndromic cases, sagittal suture synostosis occurs
most frequently (scaphocephaly; 40e55% of cases) followed
by coronal synostosis (anterior plagiocephaly; 20e25%),
metopic synostosis (trigonocephaly; 5e15%), multiple syn-
ostoses (5e15%), and lambdoid synostosis (posterior pla-
giocephaly; 0e5%).156159
Most syndromic cases are the result of a gain-of-function
mutation within the gene region responsible for the linker
between the D2 and D3 domains of the FGFR.8 A mutation in
this region may increase the receptor’s affinity for its cor-
responding FGF ligand, resulting in increased signaling that
stimulates cell differentiation and eventual suture
fusion.160 However, several additional gene mutations have
also been implicated in syndromic craniosynostosis.112,156
Several craniosynostosis syndromes will be discussed
(Table 2).
Pfeiffer syndrome
Pfeiffer syndrome is characterized by craniosynostosis,
proptosis, hypertelorism, maxillary deficiency, and a
Table 1 Skeletal dysplasias associated with FGFR3 mutations.
Disorder Mutationa Mechanism Key features Inheritanceb
Achondroplasia136,140,141 G380R (transmembrane
domain)
Gain-of-function
mutation results in
decreased
inhibition of
endochondral
ossification
Short stature,
rhizomelic limb
shortening, short
fingers and toes,
large head with
prominent
forehead, small
midface with
flattened nasal
bridge, spinal
kyphosis/lordosis,
varus/valgus
deformities
Autosomal dominant;
sporadic
Hypochondroplasia139,140,142,152 N540K (first tyrosine
kinase domain);
missense mutations
(extra-cellular domain)
Gain-of-function
mutations result in
premature fusion
of growth plates in
vertebral column
and long bones
Short stature,
short limbs,
increased head
circumference,
normal facies
Autosomal dominant;
sporadic
Thanatophoric
dysplasia140,141,143,153e155
R248C (extra-cellular
domain; type I)
K650E (second tyrosine
kinase domain; type II)
Gain-of-function
mutations result in
ligand-
independent
receptor
activation
Early death,
extremely short
limbs, redundant
skin folds, narrow
chest with short
ribs,
underdeveloped
lungs, large head,
curved thigh bones
(type I), cloverleaf
skull (type II)
Autosomal dominant;
sporadic
FGFR3, fibroblast growth factor receptor 3.
a Commonest mutation(s) is noted. Others may be documented.
b Virtually all cases of thanatophoric dysplasia result from sporadic mutations because of its early lethality.
Fibroblast growth factor 205beaked nose. Patients with Pfeiffer syndrome also have
wide thumbs and great toes that bend away from other
digits and may display brachydactyly or syndactyly. Three
variants of Pfeiffer syndrome exist: type I is associated with
FGFR1 and FGFR2 mutations; types II and III are associated
with FGFR2 mutations.161 Significant genetic heterogeneity
exists among patients with Pfeiffer syndrome. Approxi-
mately 5% of patients with type I Pfeiffer syndrome contain
a gain-of-function P252R mutation of FGFR1.161,162 This
mutation occurs at the linker region between D2 and D3,
resulting in a bulkier residue that increases the receptor’s
affinity for ligand binding and therefore excessive receptor
activation.112 The other 95% of cases are thought to be due
to sequence variants in the FGFR2 gene. Patients with type
I Pfeiffer syndrome due to an FGFR1 mutation usually
display a more favorable phenotype than patients with a
mutation of FGFR2.
Patients with types II or III Pfeiffer syndrome generally
have a more severe phenotype and worse prognosis. These
conditions result from an FGFR2 mutation. The most com-
mon mutations occur in exons IIIa and IIIc, resulting in an
unpaired cysteine residue that forms an intermolecular
disulfide bond that causes ligand-independent receptor
activation.161,163Apert syndrome
Apert syndrome is characterized by bilateral premature
fusion of the coronal suture, developmental delay, midface
hypoplasia, syndactyly of fingers and toes, and potentially
other anomolies.160,164e168 Activating mutations (S252W
and P253R) in FGFR2 are thought to be responsible for the
majority of cases and resultant brain dysmorpholo-
gies.160,165 These mutations result in increased ligand af-
finity for the receptor and therefore trigger excessive
activation. Evidence supports that the P253R mutation re-
sults in an indiscriminate increase in affinity of FGFR2 to-
ward any FGF. The S252W mutation, however, selectively
enhances FGFR2 affinity toward a subset of FGFs.169 These
genotypic differences may also cause clinical variability in
patient presentation.
Crouzon syndrome
Crouzon syndrome is due to a gain-of-function mutation in
FGFR2 that results in ligand-independent, disulfide-medi-
ated, covalent receptor dimerization and activation.165 The
disulfide bond is formed between a cysteine-cysteine
Table 2 Syndromic craniosynostoses associated with FGFR mutations.
Syndrome Mutationa,b Mechanism Key features Inheritance
Pfeiffer112,161e163 P252R (FGFR1);
several sequence
variants (FGFR2)
P252R gain-of-function
mutation results in
increased receptor
affinity for ligand
binding; FGFR2-related
gain-of-function
mutations result in
ligand-independent
receptor activation
Proptosis, hypertelorism,
maxillary hypoplasia,
beaked nose,
developmental delay
(types II and III),
cloverleaf skull (type II),
turribrachycephaly
(type III)
Autosomal dominant;
sporadic
Apert160,165,169 S252W and P253R
(FGFR2)
Gain-of-function
mutations result in
increased receptor
affinity for ligand binding
Turribrachycephaly,
midface hypoplasia,
syndactyly of fingers and
toes, varying degrees of
developmental delay
Autosomal dominant;
sporadic
Crouzon112,161,165 Several missense
mutations (FGFR2)
Gain-of-function
mutations result in
disulfide bond that
stabilizes the D3 loop to
allow for ligand-
independent receptor
activation
Proptosis, external
strabismus, mandibular
prognathism, normal
extremities, normal
intelligence
Autosomal dominant;
sporadic
Beare-Stevenson
cutis gyrata112,161,174,175
Y394C (FGFR2) Gain-of-function
mutation results in
ligand-independent
receptor activation
Midface hypoplasia,
abnormal ears, natal
teeth, widespread cutis
gyrata, acanthosis
nigricans, skin tags,
developmental delay,
pyloric stenosis, anterior
anus
Autosomal dominant;
sporadic
Jackson-Weiss161,176 C342S, C342R,
Q289P, A344G
(FGFR2)
Gain-of-function
mutations result in
ligand-dependent
receptor overactivation
Mandibular prognathism,
broad and medially
deviated great toes,
short first metatarsal,
calcaneocuboid fusion,
normal intellect
Autosomal dominant;
sporadic
Muenke112,170 P250R (FGFR3) Gain-of-function
mutation results in
increased receptor
affinity for ligand binding
Uni- or bicoronal
synostosis,
megalencephaly,
midface hypoplasia,
hypertelorism, variable
sensorineural hearing
loss, osteochondroma
Autosomal dominant;
sporadic
FGFR, fibroblast growth factor receptor.
a Commonest mutation(s) is noted. Others may be documented.
b Type I Pfeiffer syndrome is associated with a P252R mutation in FGFR1 in 5% of cases. The majority of type I and all of types II and III
Pfeiffer syndrome cases are associated with sequence variant mutations in FGFR2.
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free activation of the receptor.112 Patients with Crouzon
syndrome chiefly present with premature fusion of the
coronal sutures, mandibular prognathism, strabismus, and
proptosis.165 Unlike Apert syndrome, patients with Crouzon
syndrome typically display normal cognitive development
and normal-appearing extremities.112,161,170e172
A variant of Crouzon syndrome is Crouzonodermoskeletal
syndrome. Patients present with many of the skeletal fea-
tures of Crouzon syndrome but this condition is distin-
guished by the presence of acanthosis nigricans.Crouzonodermoskeletal syndrome is primarily associated
with mutations to FGFR3. Specifically, an A391E mutation is
thought to result in ligand-free activation of the
receptor.112,173Beare-Stevenson cutis gyrata syndrome
Beare-Stevenson cutis gyrata syndrome is also a syndromic
form of craniosynostosis caused by an FGFR2 mutation. It is
characterized by cognitive impairment, moderate-to-severe
Fibroblast growth factor 207midface hypoplasia, abnormal ears, cutis gyrata, acanthosis
nigricans, prominent umbilical stump, accessory nipples,
pyloric stenosis, and an anterior anus.112,174 A Y394C muta-
tion leads to a cysteine-cysteine disulfide bond that initiates
ligand-free activation of the receptor.161,175
Jackson-Weiss syndrome
Jackson-Weiss syndrome is characterized by mandibular
prognathism, broad and medially deviated toes, short first
metatarsals, calcaneocuboid fusions, and abnormal tar-
sals.176 It has been associated with several missense mu-
tations of FGFR2, including C342S, C342R, Q289P, and
A344G.161,176 In each case, an amino acid substitution
triggers excessive receptor activation.
Muenke syndrome
Muenke syndrome is an FGFR3-related craniosynostosis that
generates isolated coronal synostosis and overlaps pheno-
typically with Pfeiffer and Jackson-Weiss syn-
dromes.112,161,170 Patients have normal to mildly impaired
intelligence, variable uni- or bicoronal synostosis, mega-
lencephaly, midface hypoplasia, carpal-tarsal fusion, bra-
chydactyly, sensorineural hearing loss, and
osteochondroma.170,177,178 An FGFR3 P250R mutation oc-
curs between the D2 and D3 domains, promoting excessive
ligand binding through the substitution of a bulkier res-
idue.112 This causes over activation of the receptor.
Nonsyndromic craniosynostosis
Nonsyndromic craniosynostosis is characterized by isolated
premature suture fusion and no additional extra-cranial
abnormalities. Classification is based on which sutures are
fused. The genetic mechanisms of nonsyndromic variants
are less well understood than those associated with syn-
dromic craniosynostosis.179 It had been thought that mu-
tations in FGFR3 may be responsible for particular sporadic
cases. However, many of these cases were determined to
be mild syndromic variants.157 Recently, evidence has
shown a potential link between an A315Y mutation on
FGFR2 and isolated sagittal synostosis.133,157 Additionally,
in utero factors may play a role in isolated synostosis. In-
trauterine cranial constraints have been observed to induce
over expression of FGFR2 at the osteogenic fronts of cal-
varial bones in the dura and osteoblasts.180
Concluding remarks and future directions
FGFs and their associated receptors have been studied
extensively for the past 30 years. Recently, significant
research has focused on the therapeutic potential of FGF-
FGFR signaling. Beenken and Mohammadi provide an
excellent review of traditional therapeutic applications of
recombinant FGFs and small-molecule FGFR kinase in-
hibitors.4 Both in vitro and in vivo studies offer evidence as
to the physiologic roles of each FGF ligand. Phenotypic
studies of knockout mice in particular provide clues for the
specific functions of each FGF ligand and whether a ligandis required for life. As discussed above, aberrant FGF-FGFR
signaling is associated with many pathologic conditions
including cancer and craniofacial and axial skeletal abnor-
malities. Aberrant signaling has also been implicated in
cardiovascular disease, mood disorders, and potentially
metabolic syndromes. To this end, the FGF-FGFR signaling
system appears to an import therapeutic target.
To date, the therapeutic potential of FGFRs mostly
relate to their role in tumorigenesis and cancer develop-
ment. In particular, direct inhibition of FGFRs may improve
outcomes of various cancers. Proof of principle with
respect to effective treatment for malignancy comes from
many lines of evidence. The small molecule inhibitors
SU5402, PD173074, and nordihydroguaiaretic acid are effi-
cacious in the treatment of multiple myeloma cell lines
associated with deregulated FGFR3 expression.181,182
PD173074 has also been shown to induce cell cycle arrest
in FGFR2-mutated endometrial cancer cells.183 In addition,
sunitinib, a receptor tyrosine inhibitor with activity against
FGFRs, has received approval from the Food and Drug
Administration (FDA) for use in patients with renal cell
carcinoma and gastrointestinal stromal tumors.184 Inter-
estingly, potential therapeutic targets have also been
elucidated by experiments that involve the disruption of
downstream signaling after FGFR activation. The blood
cancer 8p11 myeloproliferative syndrome (EMS) is due to
constitutive dimerization of the FGFR1 kinase domain in the
setting of an inappropriate translocation.185 A mutation in
the PLCg1 binding site at Tyr766 attenuates EMS.186 A po-
tential strategy in the treatment of EMS could therefore
include the disruption of FGFR-PLCg1 signaling. The inter-
ference of the interaction of FGFR and its downstream
signaling pathways has become a conceivable therapeutic
strategy.
Many potential roles for FGF ligands to be used as
therapy also exist. FGF18 is key for physiologic bone growth
and development. FGF18/ mice demonstrate a wide va-
riety of bone and cartilage malformations including a delay
in osteogenic differentiation, closure of the calvarial su-
tures, and long-bone ossification; defective joint develop-
ment; and enlargement of the proliferating and
hypertrophic zones in long bone growth plates.187,188 Re-
combinant FGF18 has been shown to stimulate growth of
porcine and human articular chondrocytes and have an
overall anabolic effect on cartilage.189 Clinically, it may
stimulate the repair of cartilage damaged in the setting of
progressive osteoarthritis.190
Many additional therapeutic uses of FGF ligands have
been documented. FGF1 treatment can stimulate nerve
repair and may enhance nerve graft take.191 FGF1, FGF2,
and FGF4 have therapeutic promise in cardiovascular dis-
ease.192e194 Recombinant FGF2 may also provide benefit to
patients with mood disorders.195 Recombinant FGF7 im-
proves wound healing.196 Additionally, although further
investigation is needed, FGF19 and -21 and FGF20 have
potential roles in the treatment of diabetes and Parkinson’s
disease, respectively.197e199 Oppositely, inhibitors of FGF5
may aid in hair growth.200
Significant work has demonstrated the myriad develop-
mental and homeostatic processes that involve FGF-FGFR
signaling. Moving forward, ongoing research will almost
certainly uncover additional functions of the FGF-FGFR
208 C.M. Teven et al.signaling system. It is hopeful that the discovery of addi-
tional therapies that involve this system will parallel such
findings. These may come in the form of recombinant pro-
teins, small molecules, and gene therapy. At this time, the
majority of FGF-based therapies are aimed at age-related
disorders including osteoarthritis, diabetes, cardiovascular
disorders, and Parkinson’s disease. A substantial challenge
is the prevention and treatment of FGF-related disorders
that are present at birth. To this end, an even greater un-
derstanding of FGF biology will unlock additional strategies
to treat disease, both in utero and postnatally. Finally, a
new frontier in the investigation of FGF signaling relates to
our recent understanding of the role of FGFs and FGFRs in
inducing stem cell self-renewal and inhibiting stem cell
senescence.201 Stem cells have tremendous potential in the
treatment of human disease. The addition of targeted FGF
therapy to this armamentarium could augment success.
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